Will Intravenous Inron reduce blood transfusion in patients undergoing treatment for ovarian cancer
Phase 3
Completed
- Conditions
- Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
- Registration Number
- CTRI/2019/05/019378
- Lead Sponsor
- Amrita University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 69
Inclusion Criteria
age 18–75 years with normal liver and kidney function, no prior radiotherapy
and an Eastern Cooperative Oncology Group (ECOG) performance status
of =2
-Patient with epithelial ovarian cancer receiving Neoadjuvant or adjuvant chemotherapy or planned for surgery , having Hemoglobin level =10 gm/dL
Exclusion Criteria
Erythropoitin Stimulating Agent administration during chemotherapy course
-Allergic reaction to ferric carboxymaltose
- Serum ferritin >800 ng/mL OR serum trasferrin saturation >50%
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method